drugset / Trial / NCT00600691
The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy
Phase 2
Terminated
29 enrolled
University of British Columbia
Health Canada · collabMerck Frosst Canada Ltd. · collab
RandomizedSingle-groupDouble-blindTreatment
Summary
The purpose of our study is primarily to evaluate the effects of 5mg finasteride on hematuria and hematospermia commonly associated with prostate biopsies. We hypothesize that 5mg of finasteride daily for two weeks preceding TRUS prostate biopsy and one week following will reduce hematuria and hematospermia commonly seen as complications following prostate biopsy. We also hypothesize that reducing complications will decrease concern among subjects and make for a more tolerable overall procedure than compared with subjects treated with placebo.
Timeline
- Start
- 2008-03
- Primary completion
- 2011-12
- Completion
- 2011-12
Outcome
Outcome not reported
Stopped (Enrollment): “Did not achieve enrollment goal and decided to terminate early”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Finasteride | Small molecule | 5 mg | Oral |